Impact of Triple Combination Therapy for People with CF with Sinusitis Request More Information Trial Objective This observational study will assess the impact of a new triple combination CFTR modulator therapy on chronic sinusitis in adults with cystic fibrosis. This triple combination therapy is made up of the drugs, ivacaftor, tezacaftor and elexacaftor, and in previous studies has been shown to improve lung function and sweat chloride. Researchers are trying to determine if this new triple combination therapy can also improve computed tomography sinus CT scan findings, sense of smell and quality of life for people with CF with chronic sinusitis. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Adults with chronic sinusitis and cystic fibrosis who are prescribed elexacaftor-tezacaftor-ivacaftor by their clinic doctor. Age: 18-80 Gender: Any Gender Estimated Time Commitment 6 months This study will include a baseline visit lasting 2-3 hours at the beginning of the study and a follow up appointment lasting approximately 2 hours 6 months into the study. CT scans will be performed at both the baseline and follow-up visits. Participants are expected to receive monthly phone calls and take electronic surveys between the two appointments. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Connor Balkissoon 303.270.2768 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Cystic Fibrosis Foundation and the Marshall and Margherite McComb Foundation Principal Investigators Jennifer Taylor-Cousar, MD, MSCS + × Jennifer Taylor-Cousar, MD, MSCS Medical Director, Clinical Research Services Co-Director, Adult Cystic Fibrosis Program Director, Cystic Fibrosis Therapeutics Development Center Adult Program Professor Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine Division of Pediatric Pulmonary Medicine Department of Pediatrics View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective This observational study will assess the impact of a new triple combination CFTR modulator therapy on chronic sinusitis in adults with cystic fibrosis. This triple combination therapy is made up of the drugs, ivacaftor, tezacaftor and elexacaftor, and in previous studies has been shown to improve lung function and sweat chloride. Researchers are trying to determine if this new triple combination therapy can also improve computed tomography sinus CT scan findings, sense of smell and quality of life for people with CF with chronic sinusitis.